Vinnaren i pepparkakshustävlingen!
  • 4
  • 5
2020-10-21, 14:50
  #49
Moderator
Jultrollets avatar
Citat:
Ursprungligen postat av Vogly
Anmälning till studien börjar 24 oktober tydligen.

Citat:
Ursprungligen postat av QxZtVyPrQ9981AZX
Psilocybin prövas mot depression i ny studie vid Karolinska Institutet - första gången i Sverige
https://news.cision.com/se/osmond-fo...erige,c3216195
Då detta är en ny studie, alltså inte samma som i trådstarten, så hänvisar vi diskussionen om den till annan tråd. Detta för att inte förväxling ska ske.
(FB) Psilocybin prövas mot depression i ny studie vid Karolinska Institutet

/Moderator
__________________
Senast redigerad av Jultrollet 2020-10-27 kl. 16:19. Anledning: Korrigerar till ny länk då den gamla är sammanfogad
Citera
2020-12-13, 12:37
  #50
Medlem
QxZtVyPrQ9981AZXs avatar
Forskning på "magiska svampar" för att bota depression.
https://www.tv4.se/klipp/va/13309354...s13ecjm0avMUEo

Citera
2021-06-29, 23:37
  #51
Medlem
QxZtVyPrQ9981AZXs avatar
Psilocybin Therapy May Work as Well as Common Antidepressant
https://www.scientificamerican.com/a...ntidepressant/

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

https://www.globenewswire.com/news-r...epression.html

The trial is a randomised controlled, double-blinded, dose-ranging study, investigating the safety and efficacy of psilocybin therapy and comparing a 25mg and 10mg dose of COMP360 psilocybin with a 1mg dose, administered in conjunction with psychological support from specially trained therapists. The 216th patient in the trial had their psilocybin session late last week. Although the target of 216 patients has been achieved and enrolment has now been closed, all enrolled patients who are in the run-in period and have not yet had their psilocybin therapy session, will remain in the trial. This means the number of patients included in the final analysis will be approximately 230, with all psilocybin sessions expected to be completed by 8 July.

Patients are followed-up for 12 weeks after their psilocybin session. COMPASS remains on track to report data in late 2021.

Sue Stansfield PhD, Senior Vice-President, Clinical Operations, COMPASS Pathways, said, “Thank you to everyone on the team and to all our partners and trial sites who have kept this trial going over the last year, despite the pandemic. The safety of patients and of our teams has always been our first priority, and we have introduced measures such as air filtration units and therapists wearing clear masks, to ensure patients were as comfortable as possible in the midst of all the COVID precautions.”

George Goldsmith, CEO and Co-founder, COMPASS Pathways, said, “Completing recruitment to our trial is a tremendous milestone and a huge step forward towards our goal of getting psilocybin therapy to patients in need. We are fortunate to be doing this in collaboration with hundreds of talented and dedicated people from our 22 trial sites in 10 countries - including investigators, raters, study coordinators and nurses, therapists, and pharmacists – as well as our supply chain and clinical research partners. This has been an amazing effort by the whole team, who are delivering the world’s largest psilocybin therapy clinical trial, in the middle of a pandemic, and with all the uncertainties and changes brought on by national lockdowns and site closures.


Oufff satan vad snabbt det går
10 länder görs kliniska prövningar i.

"We expect to be ready to commence phase III trials as soon as we receive regulatory support to do so, based on our phase IIb results.”"



Slutet av 2021 lär bli intressant!
Citera
  • 4
  • 5

Stöd Flashback

Flashback finansieras genom donationer från våra medlemmar och besökare. Det är med hjälp av dig vi kan fortsätta erbjuda en fri samhällsdebatt. Tack för ditt stöd!

Stöd Flashback